MoonLake Immunotherapeutics reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 13.67 million compared to USD 9 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.23 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.99 USD | +3.27% | +2.79% | -30.47% |
May. 07 | MoonLake Immunotherapeutics Q1 Net Loss Widens | MT |
May. 07 | MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.47% | 2.56B | |
+15.55% | 118B | |
+12.66% | 106B | |
-2.53% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.92% | 15.56B | |
+6.19% | 13.63B | |
+28.83% | 12.27B |
- Stock Market
- Equities
- MLTX Stock
- News MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024